Targeted Technology Funds — 2012 Investments
1 investments dated 2012 · listed companies and verified rows first · show all
ViroXis Corporation, Inc.Feb 2012acquired by TFS
Mid-stage drug developer of botanical anti-viral topical prescription candidates for skin diseases; acquired by TFS Corporation in 2017.
BiotechSan Antonio, US
BoardAlan Dean(Director)Ian William David Clements(Executive Officer, Director)Paul Castella(Director)Gary Frashier(Director)
PartnerAlan Dean· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.